Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CART84 dose-escalation study in relapsed/refractory AML and T-ALL
2024-519966-31-00Phase 2Authorised
- Sponsor
- Gyala Therapeutics
- Start
- Aug 2025
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of CD84 CAR T-cells in acute myeloid leukemia (AML) and t-cell acute lymphoblastic leukemia (T-ALL) (2 arms), sponsored by Gyala Therapeutics. Primary endpoints: Safety after CART84 infusion and Overall response rate at day 30. Planned start Aug 2025; status: authorised.
02
Drugs
CD84 CAR T-cells
03
Conditions
acute myeloid leukemia (AML)t-cell acute lymphoblastic leukemia (T-ALL)
Beyond the preview
Go deeper on 2024-519966-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519966-31-00.